Samaritan Pharmaceuticals, Inc. Continues To Effectively Expand Valuable Patent Portfolio; Samaritan’s Drug Development Pipeline Consists Of 250 Possible Drug Candidates Based On Twenty-Six Patent Applications Worldwide

LAS VEGAS--(BUSINESS WIRE)--Nov. 16, 2005-- Samaritan is Currently Developing the Most Promising Niche Buster Drug Candidates to Apply to the FDA for Investigational New Drug Status (IND) Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today, it is aggressively pursuing patenting to protect and effectively expand its valuable patent portfolio worldwide. Samaritan holds the worldwide patent rights for an extensive amount of drug candidates but has focused its drug development efforts on the niche buster indications of HIV drug resistance and Alzheimer’s, believing it will lower the cost and time of clinical trials, by reducing the number of patients needed to show effectiveness.

MORE ON THIS TOPIC